These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 18374153)

  • 1. Mouse model for NRAS-induced leukemogenesis.
    Parikh C; Ren R
    Methods Enzymol; 2008; 439():15-24. PubMed ID: 18374153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.
    Parikh C; Subrahmanyam R; Ren R
    Cancer Res; 2007 Aug; 67(15):7139-46. PubMed ID: 17671181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.
    Parikh C; Subrahmanyam R; Ren R
    Blood; 2006 Oct; 108(7):2349-57. PubMed ID: 16763213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.
    Omidvar N; Kogan S; Beurlet S; le Pogam C; Janin A; West R; Noguera ME; Reboul M; Soulie A; Leboeuf C; Setterblad N; Felsher D; Lagasse E; Mohamedali A; Thomas NS; Fenaux P; Fontenay M; Pla M; Mufti GJ; Weissman I; Chomienne C; Padua RA
    Cancer Res; 2007 Dec; 67(24):11657-67. PubMed ID: 18089795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas.
    Wolf S; Rudolph C; Morgan M; Büsche G; Salguero G; Stripecke R; Schlegelberger B; Baum C; Modlich U
    Oncogene; 2013 Jun; 32(25):3028-38. PubMed ID: 22847614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling myeloid leukemia tumor suppressor gene inactivation in the mouse.
    Shannon KM; Le Beau MM; Largaespada DA; Killeen N
    Semin Cancer Biol; 2001 Jun; 11(3):191-200. PubMed ID: 11407944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiological analysis of oncogenic K-ras.
    Pérez-Mancera PA; Tuveson DA
    Methods Enzymol; 2006; 407():676-90. PubMed ID: 16757361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palmitoylation of oncogenic NRAS is essential for leukemogenesis.
    Cuiffo B; Ren R
    Blood; 2010 Apr; 115(17):3598-605. PubMed ID: 20200357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.
    Lauchle JO; Braun BS; Loh ML; Shannon K
    Pediatr Blood Cancer; 2006 May; 46(5):579-85. PubMed ID: 16261595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Proteomic approach for protein-profiling the oncogenic ras induced transformation (H-, K-, and N-Ras) in NIH/3T3 mouse embryonic fibroblasts.
    Kim S; Lee YZ; Kim YS; Bahk YY
    Proteomics; 2008 Aug; 8(15):3082-93. PubMed ID: 18601226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
    Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
    Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of ras genes in the neoplasmic transformation in animals.
    Rotkiewicz T; Słodki S; Otrocka-Domagała I
    Pol J Vet Sci; 2004; 7(1):47-52. PubMed ID: 15061485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retroviral library genetic screen identifies IRF-2 as an inhibitor of N-ras-induced growth suppression in leukemic cells.
    Passioura T; Shen S; Symonds G; Dolnikov A
    Oncogene; 2005 Nov; 24(49):7327-36. PubMed ID: 16007130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.
    Wang J; Liu Y; Li Z; Wang Z; Tan LX; Ryu MJ; Meline B; Du J; Young KH; Ranheim E; Chang Q; Zhang J
    Blood; 2011 Jul; 118(2):368-79. PubMed ID: 21586752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of murine gene expression profiles between spontaneous and radiation-induced myelogenous leukemias: stochastic and probabilistic expression variances in the former vs radiation-specific expression commonalities in the latter.
    Hirabayashi Y; Tsuboi I; Kitada K; Igarashi K; Kodama Y; Kanno J; Yoshida K; Dainiak N; Inoue T
    Exp Hematol; 2009 Feb; 37(2):195-205. PubMed ID: 19070417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered detoxification status and increased resistance to oxidative stress by K-ras transformation.
    Recktenwald CV; Kellner R; Lichtenfels R; Seliger B
    Cancer Res; 2008 Dec; 68(24):10086-93. PubMed ID: 19074874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
    Rotblat B; Ehrlich M; Haklai R; Kloog Y
    Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NADPH oxidase 1 plays a critical mediating role in oncogenic Ras-induced vascular endothelial growth factor expression.
    Komatsu D; Kato M; Nakayama J; Miyagawa S; Kamata T
    Oncogene; 2008 Aug; 27(34):4724-32. PubMed ID: 18454179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinoic acid receptors, hematopoiesis and leukemogenesis.
    Collins SJ
    Curr Opin Hematol; 2008 Jul; 15(4):346-51. PubMed ID: 18536573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A.
    Zhao H; Liu P; Zhang R; Wu M; Li D; Zhao X; Zhang C; Jiao B; Chen B; Chen Z; Ren R
    J Hematol Oncol; 2015 Dec; 8():132. PubMed ID: 26715448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.